API | imlifidase

imlifidase Report issue

Biologics Recombinant protein Experimental

AACT

Active Ingredient History

NOW

Imlifidase, brand name Idefirix, is a medication for the desensitization of highly sensitized adults needing kidney transplantation, but unlikely to receive a compatible transplant. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

imlifidase

hmpl-453

More Chemistry

Pharmacology

Mechanisms of Action:
- Fibroblast growth factor receptor 1 (Homo sapiens) ^UniProt
- Fibroblast growth factor receptor 2 (Homo sapiens) ^UniProt
- Fibroblast growth factor receptor 3 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

hmed-ides | hmpl-453 | ides

Organizations (11)

Research & Development (11)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (13)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (13)

Anti-Glomerular Basement Membrane Disease (Phase 3)

Autoimmune Diseases (Phase 3)

Bile Duct Neoplasms (Phase 2)

Cholangiocarcinoma (Phase 2)

Guillain-Barre Syndrome (Phase 2)

Healthy Volunteers (Phase 1)

Kidney Diseases (Phase 1/Phase 2)

Kidney Failure, Chronic (Phase 2)

Kidney Transplantation (Phase 3)

Mesothelioma (Phase 2)

Neoplasms (Phase 1/Phase 2)

Purpura, Thrombotic Thrombocytopenic (Phase 1/Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 21
# of Trial Organizations: 11

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue